GLP1R and chronic kidney disease: A meta-analysis involving more than 70,000 participants with type 2 diabetes (SMART-C) found that the cardiovascular benefits of SGLT-2 inhibitors, including reductions in MACE, cardiovascular death, hospitalisation for HF, and CKD progression, were consistent regardless of whether patients were receiving a GLP-1 receptor agonist at baseline [19].